Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).

Details

Ressource 1Download: PMID29115994.pdf (718.40 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_8F93552584A6
Type
Article: article from journal or magazin.
Collection
Publications
Title
Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).
Journal
BMC pharmacology & toxicology
Author(s)
Lloret-Linares C., Daali Y., Chevret S., Nieto I., Molière F., Courtet P., Galtier F., Richieri R.M., Morange S., Llorca P.M., El-Hage W., Desmidt T., Haesebaert F., Vignaud P., Holtzmann J., Cracowski J.L., Leboyer M., Yrondi A., Calvas F., Yon L., Le Corvoisier P., Doumy O., Heron K., Montange D., Davani S., Déglon J., Besson M., Desmeules J., Haffen E., Bellivier F.
ISSN
2050-6511 (Electronic)
ISSN-L
2050-6511
Publication state
Published
Issued date
07/11/2017
Peer-reviewed
Oui
Volume
18
Number
1
Pages
70
Language
english
Notes
Publication types: Clinical Study ; Journal Article ; Multicenter Study
Publication Status: epublish
Abstract
It is well known that the standard doses of a given drug may not have equivalent effects in all patients. To date, the management of depression remains mainly empirical and often poorly evaluated. The development of a personalized medicine in psychiatry may reduce treatment failure, intolerance or resistance, and hence the burden and costs of mood depressive disorders. The Geneva Cocktail Phenotypic approach presents several advantages including the "in vivo" measure of different cytochromes and transporter P-gp activities, their simultaneous determination in a single test, avoiding the influence of variability over time on phenotyping results, the administration of low dose substrates, a limited sampling strategy with an analytical method developed on DBS analysis. The goal of this project is to explore the relationship between the activity of drug-metabolizing enzymes (DME), assessed by a phenotypic approach, and the concentrations of Venlafaxine (VLX) + O-demethyl-venlafaxine (ODV), the efficacy and tolerance of VLX.
This study is a multicentre prospective non-randomized open trial. Eligible patients present a major depressive episode, MADRS over or equal to 20, treatment with VLX regardless of the dose during at least 4 weeks. The Phenotype Visit includes VLX and ODV concentration measurement. Following the oral absorption of low doses of omeprazole, midazolam, dextromethorphan, and fexofenadine, drug metabolizing enzymes activity is assessed by specific metabolite/probe concentration ratios from a sample taken 2 h after cocktail administration for CYP2C19, CYP3A4, CYP2D6; and by the determination of the limited area under the curve from the capillary blood samples taken 2-3 and 6 h after cocktail administration for CYP2C19 and P-gp. Two follow-up visits will take place between 25 and 40 days and 50-70 days after inclusion. They include assessment of efficacy, tolerance and observance. Eleven french centres are involved in recruitment, expected to be completed within approximately 2 years with 205 patients. Metabolic ratios are determined in Geneva, Switzerland.
By showing an association between drug metabolism and VLX concentrations, efficacy and tolerance, there is a hope that testing drug metabolism pathways with a phenotypical approach would help physicians in selecting and dosing antidepressants. The MARVEL study will provide an important contribution to increasing the knowledge of VLX variability and in optimizing the use of methods of personalized therapy in psychiatric settings.
ClinicalTrials.gov NCT02590185 (10/27/2015). This study is currently recruiting participants.
Keywords
ATP-Binding Cassette, Sub-Family B, Member 1/metabolism, Adolescent, Adult, Aged, Aged, 80 and over, Antidepressive Agents, Second-Generation/blood, Antidepressive Agents, Second-Generation/pharmacokinetics, Antidepressive Agents, Second-Generation/therapeutic use, Cytochrome P-450 CYP2C19/metabolism, Cytochrome P-450 CYP2D6/metabolism, Cytochrome P-450 CYP3A/metabolism, Depressive Disorder, Major/drug therapy, Depressive Disorder, Major/metabolism, Female, France, Genotype, Humans, Male, Middle Aged, Phenotype, Switzerland, Treatment Outcome, Venlafaxine Hydrochloride/blood, Venlafaxine Hydrochloride/pharmacokinetics, Venlafaxine Hydrochloride/therapeutic use, Young Adult
Pubmed
Web of science
Open Access
Yes
Create date
10/11/2017 9:23
Last modification date
20/08/2019 14:53
Usage data